me-too drug
A drug that is a slight molecular variant of an existing drug in the same class, patented to gain new exclusive marketing rights but with no demonstrated advantage over the original.
As defined in Marcia Angell on Big Pharma
Where it comes up · 2
Most important claims · 5 of 5Search all claims for “me-too drug” →
- Because a company can command a high price regardless of value, the rational strategy is to make low-risk 'me-too' drugs—slightly modifying an existing drug to win a new patent and capture the market for another 7-10 years—rather than risk a genuine breakthrough; many blockbusters come from buying small innovative firms rather than in-house innovation, so tying price to value would actually increase innovation by rewarding real risk-taking.Vincent Rajkumar on the High Price of Cancer Drugs
- Placebo-controlled trials should not be accepted for a drug treating a condition that already has treatments; trials should compare the new drug against the best available drug (or a three-arm design), which would stop companies from profiting on me-too drugs since most would prove no better and never reach market, forcing genuine innovation.Marcia Angell on Big Pharma
- Companies take top-selling drugs originally discovered in publicly funded labs, 'twiddle a molecule' enough to obtain a new patent and exclusive marketing rights, and market the result as a new drug, producing whole classes of 'me-too' drugs with no demonstrable difference between them.Marcia Angell on Big Pharma
- When Prilosec was about to lose exclusivity, the company created Nexium—essentially Prilosec with a slightly different molecule—moved Prilosec over the counter, and promoted high-cost prescription Nexium as a new and different drug, even though it was not.Marcia Angell on Big Pharma
- In the major drug companies' own SEC filings, the budget divides into R&D, marketing and administration, profits, and manufacturing costs, with R&D being the smallest category, profits roughly equal to it, and marketing and administration more than twice R&D.Marcia Angell on Big Pharma